Skip to main content
Erschienen in: Info Diabetologie 5/2021

28.10.2021 | Telemedizin | Fortbildung_CME

Kindheit so normal wie möglich

Update Typ-1-Diabetes bei Kids: Insuline, Technologie, Telemedizin

verfasst von: Priv.-Doz. Dr. med. Thomas M. Kapellen

Erschienen in: Info Diabetologie | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Auszug

Die Inzidenz von Typ-1-Diabetes bei Kindern und Jugendlichen nimmt weiter zu. Neben Stoffwechselentgleisungen bei der Manifestation sind auch Einschränkungen durch die Coronavirus-Pandemie eine Herausforderung für die Versorgung. Die telemedizinische Betreuung hat zugenommen. Weitere Technologien, die den Trend der Technisierung in der Kinderdiabetologie fortsetzen, sollen den Stoffwechsel verbessern und die diabetesbedingte Belastung reduzieren. Hier auf dem Laufenden zu bleiben, ist für Diabetesteams sehr aufwändig.
Literatur
1.
Zurück zum Zitat Cherubini V, Grimsmann JM, Akesson K et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 2020; 63:1530-1541 Cherubini V, Grimsmann JM, Akesson K et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 2020; 63:1530-1541
2.
Zurück zum Zitat Kamrath C, Mönkemöller K, Biester T et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 Pandemic in Germany. JAMA 2020 25; 324:801-804 Kamrath C, Mönkemöller K, Biester T et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 Pandemic in Germany. JAMA 2020 25; 324:801-804
3.
Zurück zum Zitat Manuwald U, Heinke P, Salzsieder E et al. Incidence trends of type 1 diabetes before and after the reunification in children up to 14 years of age in Saxony, Eastern Germany. PLoS One 2017; 12:e0183665 Manuwald U, Heinke P, Salzsieder E et al. Incidence trends of type 1 diabetes before and after the reunification in children up to 14 years of age in Saxony, Eastern Germany. PLoS One 2017; 12:e0183665
4.
Zurück zum Zitat Manuwald U, Schoffer O, Hegewald J et al. Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, East germany: a population based register study. PLoS One 2019; 14:e0218807 Manuwald U, Schoffer O, Hegewald J et al. Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, East germany: a population based register study. PLoS One 2019; 14:e0218807
5.
Zurück zum Zitat Couper JJ, Haller MJ, Greenbaum CJ et al. ISPAD clinical practice guidelines 2018: stages of type 1 diabetes mellitus in children and adolescents. Pediatric Diabetes 2018; 19 Suppl 27:20-27 Couper JJ, Haller MJ, Greenbaum CJ et al. ISPAD clinical practice guidelines 2018: stages of type 1 diabetes mellitus in children and adolescents. Pediatric Diabetes 2018; 19 Suppl 27:20-27
6.
Zurück zum Zitat Neu A, Bürger-Büsing J, Danne T et al. Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes und Jugendalter Diabetologie 2020; 15 (Suppl1):551-564 Neu A, Bürger-Büsing J, Danne T et al. Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes und Jugendalter Diabetologie 2020; 15 (Suppl1):551-564
7.
Zurück zum Zitat Holl RW, Prinz N. Versorgung von Kindern und Jugendlichen mit Diabetes - aktuelle Situation und Veränderungen der letzten 25 Jahre. In: Deutscher Gesundheitsbericht Diabetes 2021. Verlag Kirchheim Mainz. Holl RW, Prinz N. Versorgung von Kindern und Jugendlichen mit Diabetes - aktuelle Situation und Veränderungen der letzten 25 Jahre. In: Deutscher Gesundheitsbericht Diabetes 2021. Verlag Kirchheim Mainz.
8.
Zurück zum Zitat Kapellen TM. Pharmacotherapy of children and adolescents with type 1 diabetes mellitus. Handb Exp Pharmacol 2020; 261:105-118 Kapellen TM. Pharmacotherapy of children and adolescents with type 1 diabetes mellitus. Handb Exp Pharmacol 2020; 261:105-118
9.
Zurück zum Zitat Fullerton B, Siebenhofer A, Jeitler K et al. Short acting insulin analogues versus regular human insulin for adults with type 1 diabetes. Cochrane Database Syst Rev 2016:CD012161. Fullerton B, Siebenhofer A, Jeitler K et al. Short acting insulin analogues versus regular human insulin for adults with type 1 diabetes. Cochrane Database Syst Rev 2016:CD012161.
10.
Zurück zum Zitat Fath M, Danne T, Biester T et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2017; 18:903-910 Fath M, Danne T, Biester T et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2017; 18:903-910
11.
Zurück zum Zitat Thalange N, Deeb L, Iotova V et al. Insulin Degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 2015; 16:164-176 Thalange N, Deeb L, Iotova V et al. Insulin Degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 2015; 16:164-176
12.
Zurück zum Zitat Karges B, Schwandt A, Heidtmann B et al. Association of insulin pump therapy versus insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 2017; 318:1358-66 Karges B, Schwandt A, Heidtmann B et al. Association of insulin pump therapy versus insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 2017; 318:1358-66
13.
Zurück zum Zitat Mueller-Godeffroy E, Vonthein R, Ludwig-Seibold C et al. on behalf of the German working group for Pediatric Pump Therapy (agip). Psychosocial benefits of insulin pump therapy in children with type 1 diabetes and their families: the pumpkin multicenter randomized controlled trial. Pediatr Diabetes 2018; 19:1471-80 Mueller-Godeffroy E, Vonthein R, Ludwig-Seibold C et al. on behalf of the German working group for Pediatric Pump Therapy (agip). Psychosocial benefits of insulin pump therapy in children with type 1 diabetes and their families: the pumpkin multicenter randomized controlled trial. Pediatr Diabetes 2018; 19:1471-80
14.
Zurück zum Zitat Kamrath C, Tittel S, Kapellen T et al. Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry. Lancet Child Adolesc Health 2021;5:17-25 Kamrath C, Tittel S, Kapellen T et al. Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry. Lancet Child Adolesc Health 2021;5:17-25
15.
Zurück zum Zitat Tauschmann M, Herrmann JM, Freiberg C et al. Reduction in diabetic ketoacidosis and sever hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3553 subjects from the DPV Registry. Diabetes Care 2020; 34:e40-e42 Tauschmann M, Herrmann JM, Freiberg C et al. Reduction in diabetic ketoacidosis and sever hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3553 subjects from the DPV Registry. Diabetes Care 2020; 34:e40-e42
16.
Zurück zum Zitat Beato-Vibora PI, Quiros-Lopez C, Lazaro-Martin L et al. Impact of sensor-augmented pump therapy with predictive low glucose suspend function on glycemic control and patient satisfaction in adults and children with type 1 diabetes. Diabetes TechnolTher 2018; 20:738-43 Beato-Vibora PI, Quiros-Lopez C, Lazaro-Martin L et al. Impact of sensor-augmented pump therapy with predictive low glucose suspend function on glycemic control and patient satisfaction in adults and children with type 1 diabetes. Diabetes TechnolTher 2018; 20:738-43
17.
Zurück zum Zitat Biester T, Kordonouri O, Holder M et al. Let the Algorithm Do the Work: Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients. Diabetes Technol Ther. 2017;19(3):173-82. Biester T, Kordonouri O, Holder M et al. Let the Algorithm Do the Work: Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients. Diabetes Technol Ther. 2017;19(3):173-82.
18.
Zurück zum Zitat Forlenza GP, Li Z, Buckingham BA, Pinsker JE et al. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care. 2018;41(10):2155-61. Forlenza GP, Li Z, Buckingham BA, Pinsker JE et al. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care. 2018;41(10):2155-61.
19.
Zurück zum Zitat Forlenza GP, Pinhas-Hamile O, Liljenquist DR et al. Safety evaluation of the Minimed 670G system in children 7-13 years of age with type 1 diabetes. Diabetes TechnolTher Dec 26 Forlenza GP, Pinhas-Hamile O, Liljenquist DR et al. Safety evaluation of the Minimed 670G system in children 7-13 years of age with type 1 diabetes. Diabetes TechnolTher Dec 26
20.
Zurück zum Zitat Dovc K, Boughton C, Tauschmann M et al. Young children have higher variability of insulin requirements: observation during hybrid closed loop insulin delivery. Diabetes Care 2019; 62:1344-1347 Dovc K, Boughton C, Tauschmann M et al. Young children have higher variability of insulin requirements: observation during hybrid closed loop insulin delivery. Diabetes Care 2019; 62:1344-1347
21.
Zurück zum Zitat Lal RA, Basina M, Maahs DM et al. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System. Diabetes Care. 2019;42(12):2190-6. Lal RA, Basina M, Maahs DM et al. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System. Diabetes Care. 2019;42(12):2190-6.
22.
Zurück zum Zitat Tauschmann M, Thabit H, Bally L et al. APCam11 Consortium. Closed loop delivery in suboptimal controlled type 1 diabetes: a multicentre, 12 week randomized trial. Lancet 2018; 392: 1321-29 Tauschmann M, Thabit H, Bally L et al. APCam11 Consortium. Closed loop delivery in suboptimal controlled type 1 diabetes: a multicentre, 12 week randomized trial. Lancet 2018; 392: 1321-29
23.
Zurück zum Zitat Musolino G, Dovs K, Boughton C et al. Reduced burden of diabetes and improved quality of life: Experinces from unrestricted day and night hybrid closed loop use in very young children wirh type 1 diabetes. Pediatr Diabetes 2019; 20:794-99 Musolino G, Dovs K, Boughton C et al. Reduced burden of diabetes and improved quality of life: Experinces from unrestricted day and night hybrid closed loop use in very young children wirh type 1 diabetes. Pediatr Diabetes 2019; 20:794-99
24.
Zurück zum Zitat Predieri B, Leo F, Candia F et al. Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic. Front Endocrinol (Lausanne). 2020;11:595735. Predieri B, Leo F, Candia F et al. Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic. Front Endocrinol (Lausanne). 2020;11:595735.
25.
Zurück zum Zitat von Sengbusch S, Eisemann N, Mueller-Godeffroy E et al. Outcomes of monthly video consultations as an add-on to regular care for children with type 1 diabetes: A 6-month quasi-randomized clinical trial followed by an extension phase. Pediatr Diabetes. 2020;21(8):1502-15. von Sengbusch S, Eisemann N, Mueller-Godeffroy E et al. Outcomes of monthly video consultations as an add-on to regular care for children with type 1 diabetes: A 6-month quasi-randomized clinical trial followed by an extension phase. Pediatr Diabetes. 2020;21(8):1502-15.
26.
Zurück zum Zitat von Sengbusch S, Doerdelmann J, Lemke S et al. Parental expectations before and after 12-month experience with video consultations combined with regular outpatient care for children with type 1 diabetes: a qualitative study. Diabet Med. 2020:e14410. von Sengbusch S, Doerdelmann J, Lemke S et al. Parental expectations before and after 12-month experience with video consultations combined with regular outpatient care for children with type 1 diabetes: a qualitative study. Diabet Med. 2020:e14410.
27.
Zurück zum Zitat Frielitz F-S, Storm N, Hiort O, Katalinic A, von Sengbusch S. Die Erstellung eines Datenschutzkonzepts: eine Anleitung für telemedizinische Versorgungskonzepte. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2019; 62:479-485 Frielitz F-S, Storm N, Hiort O, Katalinic A, von Sengbusch S. Die Erstellung eines Datenschutzkonzepts: eine Anleitung für telemedizinische Versorgungskonzepte. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2019; 62:479-485
Metadaten
Titel
Kindheit so normal wie möglich
Update Typ-1-Diabetes bei Kids: Insuline, Technologie, Telemedizin
verfasst von
Priv.-Doz. Dr. med. Thomas M. Kapellen
Publikationsdatum
28.10.2021
Verlag
Springer Medizin
Erschienen in
Info Diabetologie / Ausgabe 5/2021
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362
DOI
https://doi.org/10.1007/s15034-021-3755-4

Weitere Artikel der Ausgabe 5/2021

Info Diabetologie 5/2021 Zur Ausgabe

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.